Aurinia Pharmaceuticals announced a complete overhaul of its C-suite on Monday, sparking both the biotech stock and hopes of an acquisition.

Large pharmaceutical companies, each with at least $20 billion in 2025 revenue, collectively reduced their workforces by more ...

Biotech stocks surged in 2025, driven by FDA approvals, M&A activity, and rising longevity investment. Explore key trends, ...

BEIJING, March 22 (Reuters) - China's Commerce Minister Wang Wentao met with the head of a leading U.S. pharmaceutical trade ...

The third quarter was a pivotal period for both the biotech and pharmaceutical sectors, with regulatory developments and an increase in business deals shaping the landscape for the industries. Public ...

This reflects the confidence pharmaceutical innovators place in Pyramid’s expanded state-of-the-art facility to deliver ...

Transaction adds TYMLOS® to portfolio alongside NUZYRA® and XHANCE® and creates a diversified portfolio expected to generate nearly $1 billion in ...

In today's Pharmaceutical Executive Daily, Pfizer warns shareholders to reject an unsolicited mini-tender offer from Tutanota ...

The war in the Middle East so far has not appreciably disrupted pharmaceutical supply chains, but the conflict could do so as ...

We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we are going to look at where BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) stands ...

Asia-Pacific leads industry growth, with North America and Europe followingDublin, March 23, 2026 (GLOBE NEWSWIRE) -- The "Cleanroom Lighting Market (2026 Edition)" report has been added to ...